WHO Approves Essential Medicines for Multiple Sclerosis while Obesity Drugs are Excluded

By Danélia Botes

August 10, 2023

The World Health Organization (WHO) has made a significant move in global health by releasing new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc). These lists include new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions among others.

The aim? To increase access to innovative medicines that show clear clinical benefits, without stretching the health budgets of low- and middle-income countries.

With a record 85 applications considered, the updated lists now include a total of 502 medicines on the EML and 361 on the EMLc.

For the first time, medicines for the treatment of Multiple Sclerosis (MS), such as cladribine, glatiramer acetate, and rituximab have been included in the EML. These drugs can delay or slow the progression of MS, offering improved access to treatment for people living with this chronic condition. MS affects approximately 2.8 million people worldwide.
However, it’s important to note that obesity drugs including glucagon-like peptide-1 receptor agonists for weight loss, were not included in the updated EML. This decision is based on the EML’s criteria, which only includes medicines that have solid evidence for safety and efficacy.

Reference url

Recent Posts

South Africa's Medical Technology Master Plan
Artificial intelligence and machine learning Data mining and machine learning Digital health solutions and mobile apps Health Equity and Access to Care Healthcare access Innovation Innovative medicines and medical devices Innovative Tech Sub-Saharan Africa Uncategorized 

South Africa’s Medical Technology Master Plan Launched

Danélia Botes

📣 Exciting news from South Africa’s #MedTech sector! 🎉 The Medical Technology Master Plan has been launched, promising a robust future for the industry. 🚀 This comprehensive roadmap outlines a strategic framework for growth and innovation, with a vision to create 1,000 new jobs in the next three years. 🚀 Not only does this plan aim to strengthen domestic capabilities, but it also sets the stage for South Africa to compete globally in the MedTech arena. 🌍 Join us on this exciting journey as we #TransformMedTech together! 💡👏💡🌍 #Innovation #Growth

Health Technology Assessment Impact
Evidence-based medicine Global Health economic evaluations Health Equity and Access to Care Health technology policies Healthcare access Healthcare decision modelling HTA Agencies HTA policies Innovation Innovative medicines and medical devices Innovative Tech Patient-centered care Policymakers Real-world evidence Real-world setting 

The Shifting Nature and Impact of Health Technology Assessment

Danélia Botes

🔍 Discover the latest trends in Health Technology Assessment and how they shape access to medical treatments. Read our latest article on the evolution of HTA methods and processes. #HealthcareInnovation #HTA #PatientCare #MedicalTechnology

📈 Stay informed on the changing landscape of health technology evaluation. #HealthPolicy #EvidenceBasedMedicine

👉 Click to learn more and join the conversation on improving healthcare outcomes. #HealthTech #MedicalResearch

Artificial intelligence and machine learning Biologics and Biosimilars Clinical guidelines and protocols Clinical toxicology Clinical trials Data mining and machine learning Drug safety Evidence-based medicine Global Health technology policies Healthcare access Innovation Innovative medicines and medical devices Innovative Tech Real-world evidence 

Drug Discovery with AI: A Glimpse into the Future of Pharmaceuticals

Danélia Botes

Discover the future of drug discovery 🚀💊! Our latest article unveils how #AI is transforming the pharmaceutical industry, from design to clinical trials. Learn about the rise of AI-discovered molecules and their impact on healthcare. #DrugDiscovery #Pharmaceuticals #Innovation #LifeSciencesConsulting

Read the full article for insights on how AI could double R&D productivity.

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER




SERVICES

QUICK LINKS

LINKEDIN
TWITTER
© 2024 Syenza™. All rights reserved.
Made with by Frogiez
schedule a meeting